Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunotherapy drug currently approved by the U.S. Food and Drug Administration (FDA) to treat several forms of cancer is also effective for treating aggressive forms of endometrial (uterine) cancer.
The UCSF researchers, led by first co-authors Alexis Combes, PhD, and Bushra Samad, MS, and senior author, Max Krummel, PhD, obtained tumor specimens from 78 UCSF clinicians, and surveyed 364 tumors biopsies from patients and categorized them into groups based on their immune microenvironment.
Scientists at the La Jolla Institute for Immunology have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Immunology Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to...
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene's antibody drug.